Medicine and Dentistry
Diseases
100%
Patient
96%
Clinical Trial
84%
Nephropathy
84%
Diabetes
84%
Canagliflozin
84%
Diabetic Nephropathy
84%
COVID-19
84%
Extracorporeal
84%
Blood Purification
84%
Acute Pancreatitis
84%
Sodium Glucose Cotransporter 2 Inhibitor
84%
Apoplexy
84%
Meta-Analysis
84%
Atrial Fibrillation
84%
Severe Acute Respiratory Syndrome Coronavirus 2
63%
Acute Kidney Injury
48%
Multiple Organ Dysfunction Syndrome
45%
Immune Response
42%
Inpatient
33%
Hazard Ratio
32%
Cardiovascular System
31%
Glomerular Filtration Rate
26%
Complication
24%
Development
21%
Therapeutic Procedure
21%
Immune Dysregulation
21%
Acute Respiratory Distress Syndrome
21%
Antivirus Agent
21%
Respiratory Disease
21%
Infection
21%
Emergency
21%
Blood
21%
Coronavirinae
21%
Apheresis
21%
Combination Therapy
21%
Cerebral Hemorrhage
19%
Placebo
13%
Chronic Kidney Disease
13%
Brain Ischemia
13%
Maturity Onset Diabetes of the Young
13%
Kidney
12%
Death
12%
Depletion
12%
Prognosis
12%
Cohort Effect
12%
Renal Replacement Therapy
12%
Mortality Rate
12%
Organ
12%
Pancreas
12%
Nursing and Health Professions
Clinical Evaluation
84%
Diabetes Mellitus
84%
Canagliflozin
84%
Kidney Disease
84%
Diabetic Nephropathy
84%
Sodium Glucose Cotransporter 2 Inhibitor
84%
Meta Analysis
84%
Atrial Fibrillation
84%
Hazard Ratio
53%
Estimated Glomerular Filtration Rate
42%
Brain Hemorrhage
31%
Placebo
21%
Patient
21%
Non Insulin Dependent Diabetes Mellitus
21%
Chronic Kidney Failure
21%
Brain Ischemia
21%
Electric Potential
10%
Marker
10%
Albuminuria
10%
Protection
10%
Follow up
10%
Pharmacology, Toxicology and Pharmaceutical Science
Hyperkalemia
84%
Sodium Zirconium Cyclosilicate
72%
Potassium
60%
Chronic Kidney Failure
24%
Heart Failure
24%
Aldosterone
24%
Angiotensin
24%
Renin
24%
Diabetes Mellitus
12%
Randomized Clinical Trial
12%
Drug
12%
Pharmacokinetics
12%
Mortality
12%
Sudden Death
12%
Resin
12%
Heart Arrhythmia
12%
Patiromer
12%
Adverse Event
12%
Potassium Sparing Diuretic Agent
12%
Clinical Trial
12%